Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018

  • ID: 4576074
  • Report
  • 50 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Ardelyx Inc
  • Daiichi Sankyo Co Ltd
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • MORE
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights:

This latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ardelyx Inc
  • Daiichi Sankyo Co Ltd
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • MORE
Introduction

Report Coverage

Hyperphosphatemia In Chronic Kidney Disease - Overview

Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development

Ardelyx Inc

Daiichi Sankyo Co Ltd

Medice Arzneimittel Putter GmbH & Co KG

OPKO Health Inc

PDX Pharmaceuticals LLC

Shield Therapeutics Plc

Spectrum Pharmaceuticals Inc

Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles

CGN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-2330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fermagate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niacinamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Hyperphosphatemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPI-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products

Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones

Featured News & Press Releases

Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings

Jan 06, 2017: Shield Therapeutics Provides Update on PT20

May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia

Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis

Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation

May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb

Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2018

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ardelyx Inc
  • Daiichi Sankyo Co Ltd
  • Medice Arzneimittel Putter GmbH & Co KG
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • Spectrum Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll